Stryker Corp. said on Monday that its Stryker Howmedica Osteonics division has received US Food and Drug Administration clearance to market its Trident Ceramic Acetabular Insert, a ceramic-on-ceramic hip replacement.
Stryker said that lab studies had shown that the ceramic-on-ceramic replacements demonstrated significantly lower wear than conventional hip replacements, including polyethylene-on-metal and metal-on-metal articulations. The firm said its study, which included more than 1,100 patients, was the first and only clinical trial of ceramic-on-ceramic hip implants to ever be presented before an FDA panel for review.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!